Evidence map›Paper›PMID 33113586›Full record

ReviewFEBS letters2020

Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas.

Hugo R de Jonge, Maria C Ardelean, Marcel J C Bijvelds, Paola Vergani

Open access · hybridAbstract readReview
In one paragraph

Review in FEBS letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Hugo R de JongeDepartment of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0001-7596-7433
Maria C ArdeleanDepartment of Neuroscience, Physiology and Pharmacology, University College London, UK.
Marcel J C BijveldsDepartment of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-0814-188X
Paola VerganiDepartment of Neuroscience, Physiology and Pharmacology, University College London, UK.ORCID 0000-0002-5422-4662
Erasmus MC · NLNatural England · GBUniversity College London · GB

Funding

Medical Research Council G0501200Wellcome Trust 218411/Z/19/Z
6 · The paper itself

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) is an unusual ABC transporter. It acts as an anion-selective channel that drives osmotic fluid transport across many epithelia. In the gut, CFTR is crucial for maintaining fluid and acid-base homeostasis, and its activity is tightly controlled by multiple neuro-endocrine factors. However, microbial toxins can disrupt this intricate control mechanism and trigger protracted activation of CFTR. This results in the massive faecal water loss, metabolic acidosis and dehydration that characterize secretory diarrhoeas, a major cause of malnutrition and death of children under 5 years of age. Compounds that inhibit CFTR could improve emergency treatment of diarrhoeal disease. Drawing on recent structural and functional insight, we discuss how existing CFTR inhibitors function at the molecular and cellular level. We compare their mechanisms of action to those of inhibitors of related ABC transporters, revealing some unexpected features of drug action on CFTR. Although challenges remain, especially relating to the practical effectiveness of currently available CFTR inhibitors, we discuss how recent technological advances might help develop therapies to better address this important global health need.

Indexed as

AnimalsCystic Fibrosis Transmembrane Conductance RegulatorDiarrheaHumansIntestinal MucosaModels, MolecularProtein DomainsCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCFTR pharmacologycholeracyclic AMPcyclic GMPenterocyteG907 compoundglibenclamideion-channel gatingsecretory diarrheazosuquidar

Identifiers

PMID33113586
PMCPMC7756540
OpenAlexW3097913989

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.